

We innovate to create!



June 2023

Jason Zhou, CEO

jason.zhou@zymeron.com

Drug Reformulation and Repurposing

Leverage the 505(b)(2) regulatory pathway for rapid development of improved medicines in niche markets where clinical gaps or opportunities exist.

Develop dual-purpose chem/bio/rad medical countermeasures (CBRN-MCM).

